title: Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
abstract: BACKGROUND
  Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease.
  
  
  METHODS
  To characterize the features of t(6;11) AML, the authors searched the Cancer and Leukemia Group B (CALGB) cytogenetic database comprising 2667 adults with newly diagnosed, de novo AML and identified 16 patients (0.6%) with t(6;11). A review of the literature identified 33 adults with de novo t(6;11) AML for whom survival data were available.
  
  
  RESULTS
  CALGB patients had a median age of 45 years (range, 22-65 years) and commonly presented with French-American-British (FAB) subtype M4 or M5 (81%). Gingival involvement at presentation was common (31%). All patients with gingival involvement had FAB M4. Compared with other patients with M4 AML in the CALGB database (n = 429), patients with M4 and t(6;11) (n = 7) had a higher frequency of gingival hypertrophy at presentation (71% vs. 17%, P = 0.003). Patients with t(6;11) were more likely to be African American (P = 0.02) and to die during induction (P = 0.03) than those without t(6;11). The complete response (CR) rate was 69% (11 of 16 patients), and CR duration was short (median, 9 months). The estimated probability of 2-year survival was 13%. Both long-term survivors received allogeneic stem cell transplantation. The estimated probability of 2-year survival of patients reported in the literature was 15%.
  
  
  CONCLUSIONS
  Although the patient sample was small, the authors suggested that investigational approaches, including allogeneic transplantation, be considered for adults with t(6;11) AML.
authors.affiliation: Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus 43210, USA. blum-1@medctr.osu.edu
authors.forename: William
authors.initials: W
authors.lastname: Blum
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Mrózek
authors.forename: Amy S
authors.initials: AS
authors.lastname: Ruppert
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Carroll
authors.forename: Kathleen W
authors.initials: KW
authors.lastname: Rao
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Pettenati
authors.forename: John
authors.initials: J
authors.lastname: Anastasi
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D002880:Chromosomes, Human, Pair 11; D002896:Chromosomes, Human, Pair 6; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014178:Translocation, Genetic; D016896:Treatment Outcome